

IMPORTANT NOTE

- This session is being recorded so if you do not wish your face or voice to be recorded, please make sure your microphone and camera are off.
- Meeting etiquette If you are not speaking, please make sure your microphone is muted.
- Please put any questions in the chat and we can pick them up to respond



NHS Type 2 Diabetes Path to Remission Programme in LLR

Referrer support session

29th November 2023

MES



MOMENTA NEWCASTLE

Agenda



- Welcome, questions, recording
- Background and benefits
- The programme
- Roles and responsibilities, referral pathways
- Medications adjustments
- Searches and referrals
- Next steps





Welcome and Introduction – Becky Hartlett

- What is this service and who is it for?
- Who are Momenta Newcastle?
- What is the role of General Practice in this programme?





Background and benefits



Research

- Studies: DiRECT, DROPLET
 - 'Remission' of T2D possible
- Intervention group at 12 mths:
 - 24% lost 15kg+
 - 46% achieved remission (70% retained at 24 mths)
 - Fewer adverse events
- Remission closely linked to weight loss
- Remission: HbA1c
 <48mmol/mol, >6 mths, no meds

Benefits

Patients:

- Weight loss, T2D remission
- Reduction in medications (av. 50%)
- Impact on comorbidities
- Healthy living / Quality of life
- 12 month programme & TDR free
- Participant case studies
- Practices:
 - Free service (NHSE-commissioned)
 - Referrals: WM Enhanced Service
 - Anecdotal: Reduces demands on practice by successful participants (weight loss, impact on comorbidities, peer support). Also medications reviews
 - Extensive support



Framework and Momenta



NHS England approach

- Piloted as NHS Low Calorie
 Diet (2020+) in 20 ICBs
- Similar emerging results to DiRECT
- Now a national Framework (like NDPP):
 - NHS Type 2 Diabetes Path to Remission Programme (T2DR)
 - Design similar to DiRECT
 - Jointly commissioned w' ICB

Momenta Newcastle

- T2DR service provider: Momenta
- Delivering since 2020
 - Originally: Birmingham & Solihull
 - Now in 13 ICBs + others
 - Including SY, GM, BSOL, C&W
- Early outcomes in line with DiRECT / NHSE pilot:
 - 11-13% weight loss at 3 months
 - Maintained into Phase 3
 - Positive uptake (70-80%)
 - Helps address health inequalities



NHS

Agenda

- Welcome, questions, recording
- Background and benefits

The programme

- Roles and responsibilities, referral pathways
- Medications adjustments
- Searches and referrals
- Next steps



NHS Type 2 Diabetes Path to Remission



- Follows principles of DiRECT, delivered by trained Coaches
- Three phases over 12 months, ALL free to participants:
 - 12 weeks: 8-900 calories/day TDR products
 - 6 weeks: Real food reintroduction
 - 7-8 months: Building healthy eating and activity habits into daily life
 - Plus: TDR Rescue package for those relapsing (>2kg regain)
- Delivery format: In-person 1:1 clinic or Digital
- 500 'starters' over 2 years to 31 August 2025



Eligibility criteria



Inclusion

Aged 18-65

- T2D diagnosis within last 6 years
- BMI >=27kg/m² (>=25kg/m² if BAME origin)
- Attended monitoring and diabetes review in last 12 months
- HbA1c within 12 months:
 - If on diabetes medication, HbA1c >=43 mmol/mol (6.1%)
 - If not on diabetes medication, HbA1c >=48 mmol/mol (6.5%)
 - In all cases, HbA1c must be <=87 mmol/mol
 (10.1%)

Exclusion

- Current insulin user
- Currently breastfeeding
- Pregnant or planning pregnancy within 6 mths
- Heart attack or stroke in last 6 months; severe heart failure (New York Heart Association grade 3 or 4); severe renal impairment (most recent eGFR <30mls/min/1.73m2); active liver disease (not including NAFLD); active substance use disorder; active eating disorder; porphyria; or known proliferative retinopathy that has not been treated
- Had bariatric surgery
 - Health professional assessment; or for whom safe and robust medications adjustment is not practical in a primary care setting

NHS Low Calorie Diet Programme Momenta participant journey





Participant experience: Sessions and resources



NHS

MOMENTA NEWCASTLE

Meal replacement products

- ~40+ products (vegan options available)
- Participants order directly (voucher codes provided, support available)
 - Free next-day delivery to home / office
 - Includes 12-week TDR, transition & Reset plan if required
 - Example link: Phase 1 | Exante UK (exantediet.com)
- No cost to participants









Participant resources





• TDR booklet





- Workbook
 - Session overview
 - Content & explanations
 - Activities and quizzes
 - Goals and targets
 - Backup information
 - Safety information



 Trackers e.g. weight, activity, behaviours, specifics



- EXi app (12 mths premium)
- Wallet card
- Pedometer



Agenda



- Welcome, questions, recording
- Background and benefits
- The programme


Roles and responsibilities, referral pathways

- Medications adjustments
- Searches and referrals
- Next steps



NHS T2DR: GP practice & provider responsibilities






Search-based referrals minimise patient travel & waiting times



Identifying interested patients








Patient information



- Patient landing page for invitation texts, social media
 - <u>https://momentanewcastle.com/t2dr-llr</u>




Agenda



- Welcome, questions, recording
- Background and benefits
- The programme
- Roles and responsibilities, referral pathways
- Medications adjustments
- Searches and referrals
- Next steps




Deprescribing: First day of TDR



- Starting medications more familiar than stopping to most
- Comprehensive NHSE Expert Reference Group guidance
 - Safe, evidence-based, pragmatic
 - More conservative than DiRECT
 - Clinical responsibility remains with referring GP
 - Do not replace clinical judgement





MOMENTA NEWCASTLE

Which glucose-lowering agents are safe with TDR?



Class of medication	Examples of drugs	Is this safe with TDR?
Biguanides	Metformin	Yes – safe
Sulfonylureas	Gliclazide, Glibenclamide, Glimepiride	No – risk of hypoglycaemia
Meglitinides	Repaglinide, Nateglinide	No – risk of hypoglycaemia
Thiazolidinediones	Piogliazone	Yes - safe
DPP4 inhibitors (-gliptins)	Linagliptin, Alogliptin, Sitagliptin, Saxagliptin, Vildagliptin	Yes - safe
SGLT2 inhibitors (-flozins)	Dapagliflozin, Canagliflozin, Empagliflozin, Ertugliflozin	No - risk of ketoacidosis
GLP-1 analogues (-tides)	Exenatide, Dulaglitide, Liraglutide, Lixisenatide, Semaglutide	Yes - safe
Alpha-glucosidase inhibitors	Acarbose	Yes – safe

(insulin is not included here as people treated with insulin are not eligible for the NHS LCD Programme pilots)

NHS England and NHS Improvement



Restarting glucose-lowering agents MHS

If Momenta flags that blood glucose is >15, or HbA1c at 6 or 12 months has risen:


- Metformin first line and is also safe in TDR
- Pioglitazone or DPP4 inhibitors are also safe in TDR

Sulfonylureas, meglitinides or SGLT2 inhibitors MUST NOT be used during TDR for safety reasons

If insulin initiation is deemed clinically necessary at any stage patients MUST stop the programme



Adjusting BP-lowering agents




Commence total diet replacement (TDR) products




NFS

Which BP medication to adjust? MHS





Subsequent BP agent adjustment



Blood pressure too high

- SBP 160-179 OR DBP 100-119 : Increase or uptitrate as per NICE Guideline
- SBP ≥180 OR DBP ≥ 120: Same day contact with GP practice. Increase/uptitrate per NICE



 SBP<90 or DBP<60 or postural symptoms reported: Repeat the same process for BP adjustment (on previous slide)

Agents being used specifically and solely for managing BP in a particular patient, are the priority for adjustment



Medications needing adjustment: Weight / dietary changes



Some medications may need to be adjusted due to changes in body weight or dietary intake

Some may be prescribed or administered by other services or settings

Ask yourself 'if someone lost weight or had a major dietary change, is the dose of this medicine likely to need adjustment?'

Responsibility of referrer to make sure that processes are in place for medications to be adjusted

If this cannot be done safely then the patient should not be referred to the T2DR programme



Examples – not exhaustive



- Warfarin
- Direct oral anticoagulants (DOACs)
- Digoxin
- Phenytoin
- Ciclosporin
- Antifungals voriconazole
- Long term antibiotic therapy (e.g. isoniazid) Low molecular weight heparin
- Infliximab (and other biologics)
- Long term antibiotic therapy (e.g. macrolides, aminoglycosides, fluoroquinolones, beta lactams)



Agenda



- Welcome, questions, recording
- Background and benefits
- The programme
- Roles and responsibilities, referral pathways
- Medications adjustments

Searches and referrals

Next steps



Making a successful referral



Step 1: Identify & invite eligible patients

Search, screen and invite: searches, template SMS / letter, patient landing page Opportunistically: Discuss at diagnosis, annual review, patient request Bespoke: Patient event

Step 2: Referral appointment, including medications adjustments

Appointment (typically 15 mins): Explain programme and discuss medication changes Make patient aware medication changes to start on day 1 of TDR Provide patient with copy of MAF

Step 3: Send referral

Ensure all sections on referral form and MAF are fully completed and email to: momenta.t2dr-llr@nhs.net





Clinical System Searches

- Friday 3rd November 2023 - LHIS added a post on their LHIS <u>LHIS</u> <u>Primary Care Resource</u> <u>channel</u> on MS Teams containing:
 - A support guide for EMIS and SystmOne practices
 - The link to the EMIS import file


EMIS Web Report Location

EMIS Web reports are available for download using the link below to the LHIS Primary Care Resource MS Teams channel.

Type 2 Diabetes Remission Programme Resources

SystmOne Report Location

SystmOne reports are already available for use and can be located as shown below.





PRISM Referral and Medications Adjustment Form



PRISM Web (EMIS)

On the PRISM Web home page enter the name of the pathway in the search bar and c

Search pathways	
Search: T2DR (Di	vay OResource OLeaflet OSelf-referral form OReferral Criteria OAll abetes Remission) Go ways Updated Pathways
ne pathway will	be displayed – click on the <u>link</u>



SystmOne

From the PRISM Dashboard Click Search PRISM Pathways button

Other Details Exact date & time				
	▼ Mon 11 Sep 2023 ▼ 09:08 ► ×			
	Changing the consultation date will affe	ct all other data entered. To avoid this, cancel and press th	e Next button Hide Warning	
Content 2WW A B C D	E F G H I J K L M N O P Q R	S T U V W XYZ PRISM Resources	Launch Protocol Select a protocol to Jaunch	
PRI Pathway Implement		Leicester City Clinical C West Leicestershire Clinical C East Leicestershire & Rutland Clinical C	commissioning Group	M Muddimer on 16 Aug 2023 12:08 Diabetic Eye Screening PRISM to Unknown Diabetic Eye Screening PRISM Pathway Accessed
Search PRISM Pathways	Search PRI	SM Resources Ft	2 Launcher	Outbound referral O- PRISM Diabetic Eye Screening - questionnaire started - (finalised: 16 Aug 2023 12:08)
	ROM Reserve Relivey Dasbased Advice & Guidance available at UHL PRISM Web	M N O P Q R S T U New UHL GP News Alerts Quick Reference Guides		
_	Resources- New & Updated Pathways	Quick Reference Guides		
	Useful Links	Contact Us		
			-	
	Systmöne Electronic	c Referral Dashboard		
Please Contact <u>PRSM Admin</u> fo System developed by Leicester		: Refemal Dashboard	Copyright LHIS 2020 V3 January 2020	
Please Contact PIOSM Admin to System developed by Leicester	or enguines	; Referal Dashboard	Copyright LHIS 2020 V3 January 2020	Show recordings from other templates Draw empty recordings



PRISM referral form



	Implementation	-			
PRI	SM Pathway and Refer	ral Implementation SysteM			Contact Us
Home	Useful Links	ory of Service PRISM	A Survey		
	Patient meets the	Medication Adjustment	Any other medication adjustments	Additional Clinical information	Additional Administration information
athway: T	2DR (Diabetes Remissio	on)v2 Patient Leaflets			
	This form is for referring eli Calorie Diet.	igible patients to the NHS Ty	pe 2 Diabetes Path to Remis	sion (T2DR) Programme, fo	rmerly known as the NHS Low
l	t provides patient choice o				eks of 800-900 kcal/day formula
C	liet, almed at supporting si	ignificant weight loss and po		abetes.	
	nclusion Critoria				
	nclusion Criteria	nclusive and diagnosed with	7		
A	Aged between 18 and 65 in		Type 2 Diabetes within the la	ist 6 years	
	Aged between 18 and 65 in BMI greater than 27kg/m Attended monitoring and	n2 (adjusted to greater than a d diabetes review in last 12 n	Type 2 Diabetes within the la 25kg/m2 in people of BAME o nonths (including retinal scree	ist 6 years prigin)	tinued annual reviews, even if
	Aged between 18 and 65 in BMI greater than 27kg/m Attended monitoring and	n2 (adjusted to greater than a d diabetes review in last 12 n newly diagnosed no need to	Type 2 Diabetes within the la 25kg/m2 in people of BAME o nonths (including retinal scree	ist 6 years prigin)	tinued annual reviews, even if
	Aged between 18 and 65 in BMI greater than 27kg/m Attended monitoring and remission achieved. (If m HbA1c wihtin 12 months • if on diabetes medicat	n2 (adjusted to greater than a d diabetes review in last 12 m newly diagnosed no need to s tion HbA1c greater than or e	Type 2 Diabetes within the la 25kg/m2 in people of BAME of nonths (including retinal screed wait for retinal screening) qual to 43 mmol/mol	ist 6 years prigin)	tinued annual reviews, even if
	Aged between 18 and 65 in BMI greater than 27kg/m Attended monitoring and remission achieved. (If n HbA1c wihtin 12 months • if on diabetes medicat • if not on diabetes medicat	n2 (adjusted to greater than d diabetes review in last 12 n newly diagnosed no need to	Type 2 Diabetes within the la 25kg/m2 in people of BAME of nonths (including retinal scree wait for retinal screening) qual to 43 mmol/mol or equal to 48 mmol/mol	ist 6 years prigin)	tinued annual reviews, even if
F	Aged between 18 and 65 in BMI greater than 27kg/m Attended monitoring and remission achieved. (If n HbA1c wihtin 12 months • if on diabetes medicat • if not on diabetes medicat • in all cases HbA1c mu Please note the selected c	n2 (adjusted to greater than i d diabetes review in last 12 n rewly diagnosed no need to i tion HbA1c greater than or e dication HbA1c greater than ust be equal to or less than 8	Type 2 Diabetes within the la 25kg/m2 in people of BAME of nonths (including retinal screed wait for retinal screening) qual to 43 mmol/mol or equal to 48 mmol/mol 57 mmol/mol	ust 6 years origin) ening) and committed to con	tinued annual reviews, even if e auto populated into the clinical
Fr Fr	Aged between 18 and 65 in BMI greater than 27kg/m Attended monitoring and remission achieved. (If n HbA1c wihtin 12 months • if on diabetes medicat • if not on diabetes medicat • in all cases HbA1c mu Please note the selected c eferral letter	n2 (adjusted to greater than 2 d'diabetes review in last 12 n rewly diagnosed no need to ition HbA1c greater than or e dication HbA1c greater than ust be equal to or less than 8 onsultations, medication, kn	Type 2 Diabetes within the la 25kg/m2 in people of BAME of nonths (including retinal screed wait for retinal screening) qual to 43 mmol/mol or equal to 48 mmol/mol 77 mmol/mol own drug allergies, investigati	ust 6 years origin) ening) and committed to con	
Fr Fr	Aged between 18 and 65 in BMI greater than 27kg/m Attended monitoring and remission achieved. (If n HbA1c wihtin 12 months • if on diabetes medicat • if not on diabetes medicat • in all cases HbA1c mu Please note the selected c eferral letter	n2 (adjusted to greater than i d diabetes review in last 12 n rewly diagnosed no need to i tion HbA1c greater than or e dication HbA1c greater than ust be equal to or less than 8	Type 2 Diabetes within the la 25kg/m2 in people of BAME of nonths (including retinal screed wait for retinal screening) qual to 43 mmol/mol or equal to 48 mmol/mol 77 mmol/mol own drug allergies, investigati	ust 6 years origin) ening) and committed to con	
Fr Fr	Aged between 18 and 65 in BMI greater than 27kg/m Attended monitoring and remission achieved. (If n HbA1c wihtin 12 months i f on diabetes medicat i f not on diabetes medicat i n all cases HbA1c mu Please note the selected co eferral letter LR Type 2 Diabetes Ren	n2 (adjusted to greater than 2 d'diabetes review in last 12 n rewly diagnosed no need to ition HbA1c greater than or e dication HbA1c greater than ust be equal to or less than 8 onsultations, medication, kn	Type 2 Diabetes within the la 25kg/m2 in people of BAME of nonths (including retinal screed wait for retinal screening) qual to 43 mmol/mol or equal to 48 mmol/mol 77 mmol/mol own drug allergies, investigati	ust 6 years origin) ening) and committed to con	
F r L	Aged between 18 and 65 in BMI greater than 27kg/m Attended monitoring and remission achieved. (If n HbA1c wihtin 12 months i f on diabetes medicat i f not on diabetes medicat i n all cases HbA1c mu Please note the selected co eferral letter LR Type 2 Diabetes Ren	n2 (adjusted to greater than 2 d'diabetes review in last 12 n rewly diagnosed no need to ition HbA1c greater than or e dication HbA1c greater than ust be equal to or less than 8 onsultations, medication, kn	Type 2 Diabetes within the la 25kg/m2 in people of BAME of nonths (including retinal screed wait for retinal screening) qual to 43 mmol/mol or equal to 48 mmol/mol 77 mmol/mol own drug allergies, investigati	ust 6 years origin) ening) and committed to con	
Fr Exclusion	Aged between 18 and 65 in BMI greater than 27kg/m Attended monitoring and remission achieved. (If n HbA1c wihtin 12 months i f on diabetes medicat i f not on diabetes medicat i n all cases HbA1c mu Please note the selected co eferral letter LR Type 2 Diabetes Ren	n2 (adjusted to greater than 2 d'diabetes review in last 12 n rewly diagnosed no need to tion HbA1c greater than or e dication HbA1c greater than ust be equal to or less than 8 onsultations, medication, kn nission Programme V2 (491	Type 2 Diabetes within the la 25kg/m2 in people of BAME of nonths (including retinal screed wait for retinal screening) qual to 43 mmol/mol or equal to 48 mmol/mol 77 mmol/mol own drug allergies, investigati	ust 6 years origin) ening) and committed to con	
Fr Exclusion	Aged between 18 and 65 in BMI greater than 27Kg/m Attended monitoring and remission achieved. (If n HbA1c wihtin 12 months • if on diabetes medicat • if not on diabetes medicat • if not on diabetes medicat • in all cases HbA1c mu Please note the selected c eferral letter LLR Type 2 Diabetes Ren criteria ving are exclusion criter	n2 (adjusted to greater than 2 d'diabetes review in last 12 n rewly diagnosed no need to tion HbA1c greater than or e dication HbA1c greater than ust be equal to or less than 8 onsultations, medication, kn nission Programme V2 (491	Type 2 Diabetes within the la 25kg/m2 in people of BAME of nonths (including retinal screed wait for retinal screening) qual to 43 mmol/mol or equal to 48 mmol/mol 77 mmol/mol own drug allergies, investigati	ust 6 years origin) ening) and committed to con	
Fr Current in:	Aged between 18 and 65 in BMI greater than 27Kg/m Attended monitoring and remission achieved. (If n HbA1c wihtin 12 months • if on diabetes medicat • if not on diabetes medicat • if not on diabetes medicat • in all cases HbA1c mu Please note the selected c eferral letter LLR Type 2 Diabetes Ren criteria ving are exclusion criter	n2 (adjusted to greater than 2 d'diabetes review in last 12 n rewly diagnosed no need to tion HbA1c greater than or e dication HbA1c greater than ust be equal to or less than 8 onsultations, medication, kn nission Programme V2 (491	Type 2 Diabetes within the la 25kg/m2 in people of BAME of nonths (including retinal screed wait for retinal screening) qual to 43 mmol/mol or equal to 48 mmol/mol 77 mmol/mol own drug allergies, investigati	ust 6 years origin) ening) and committed to con	
Exclusion Current in: Current in:	Aged between 18 and 65 in BMI greater than 27Kg/m Attended monitoring and remission achieved. (If n HbA1c wihtin 12 months • if on diabetes medicat • if not on diabetes medicat • in all cases HbA1c mu Please note the selected c eferral letter LLR Type 2 Diabetes Rem criteria wing are exclusion criter sulin user breastfieeding	n2 (adjusted to greater than 2 d'diabetes review in last 12 n rewly diagnosed no need to tion HbA1c greater than or e dication HbA1c greater than ust be equal to or less than 8 onsultations, medication, kn nission Programme V2 (491	Type 2 Diabetes within the la 25kg/m2 in people of BAME of nonths (including retinal scree wait for retinal screening) qual to 43 mmol/mol or equal to 48 mmol/mol 7 mmol/mol own drug allergies, investigat	ust 6 years origin) ening) and committed to con	
Exclusion The follow Currently I Pregnant	Aged between 18 and 65 in BMI greater than 27Kg/m Attended monitoring and remission achieved. (If n HbA1c wihtin 12 months • if on diabetes medicat • if not on diabetes medicat • in all cases HbA1c mu Please note the selected c eferral letter LLR Type 2 Diabetes Rem criteria wing are exclusion criter sulin user breastfieeding	n2 (adjusted to greater than 1 d diabetes review in last 12 n rewly diagnosed no need to it ion HbA1c greater than or e dication HbA1c greater than ust be equal to or less than 8 onsultations, medication, kn nission Programme V2 (49) ia for patients	Type 2 Diabetes within the la 25kg/m2 in people of BAME of nonths (including retinal scree wait for retinal screening) qual to 43 mmol/mol or equal to 48 mmol/mol 7 mmol/mol own drug allergies, investigat	ust 6 years origin) ening) and committed to con	
Exclusion The follow Current in: Currently I Pregnant of Had Baria	Aged between 18 and 65 in BMI greater than 27Kg/m Attended monitoring and remission achieved. (If n HbA1c wihtin 12 months i fi on diabetes medicat i fi not on diabetes medicat i fi not an diabetes medicat i nall cases HbA1c mu Please note the selected c eferral letter LLR Type 2 Diabetes Rem criteria wing are exclusion criter sulin user breastfeeding or planning to become pre	n2 (adjusted to greater than i d diabetes review in last 12 n rewly diagnosed no need to i ton HbA1c greater than or e dication HbA1c greater than ust be equal to or less than 8 onsultations, medication, kn nission Programme V2 (491 ia for patients	Type 2 Diabetes within the la 25kg/m2 in people of BAME of nonths (including retinal scree wait for retinal screening) qual to 43 mmol/mol or equal to 48 mmol/mol 7 mmol/mol own drug allergies, investigat	ust 6 years origin) ening) and committed to con	



PRISM referral form



PRISM Pathway and Re					NHS
PRISM Pathway and Refer	-				ontact Us
Home Useful Links	PRISMportal	Change service	Directory of Service	PRISM Survey	
Patient meets the Medicatio	n Adjustment Med	dication Adjustment changes	Any other medication adjustments	Additional Clinical information	Additional Administration information
I confirm that the patient meets t	he above criteria *	○ Yes			
Medication Adjustment					
currently taking need to be ac patient begins the Meal Replac Medication Adjustment changes		● Yes ○No			
Metformin medic	ation adjustment	⊖Yes ⊖No			
DPP4 inhibitor medic	ation adjustment *	⊖Yes ⊖No			
GLP-1 medic	ation adjustment *	⊖Yes ⊖No			
Pioglitazone medic	ation adjustment *	⊖Yes ⊖No			
Acarbose medic	ation adjustment *	⊖Yes ⊖No			
Ace inhibitor medic	ation adjustment	⊖Yes ⊖No			



PRISM referral form



PRI	SM Pathway an					ontact Us
Home	Useful Links			Directory of Service	PRISM Survey	
Patient m crite		dication Adjustment	Medication Adjustment changes	Any other medication adjustments	Additional Clinical information	Additional Administratio information
Ad	ditional information	n relevant to this referral				
dditional	Administration i	nformation				
hav	e with the service onfirm that the pat	st contact the patient will is via telephone. Please tient is able to effectively communicate in English	◯ Yes my patient is al	ole to communicate effectively res an interpreter (this may b ial discussion		
ls ti	ne patient happy to	o be contacted via email				
Can the s	ervice leave a void	* cemail (either landline or mobile)				
			⊖Yes ⊖No			

It is important they know what they need to do with their medication on the day they start the FIRST DAY OF MEAL REPLACEMENT PRODUCTS

Please send your referral from the practice nhs.net email account to momenta.t2dr-LLR@nhs.net




Top Tips: Searches and Referrals

Searches

- Sense check and manual screen to confirm eligibility / appropriateness


NHS

- Historical coding challenges
- Long lists can be reviewed and invited in batches or triaged
- Referral And Medications Adjustment Form (PRISM)
 - Confirm eligibility criteria are met before proceeding
 - Ensure that up to date BMI, HbA1c and date of diagnosis are captured in the patient record before completing PRISM referral.
 - Ensure patient receives a copy of the Medication Adjustment section of the referral letter generated and they are clear what needs to be stopped.
 - If no medications need adjusting you must still complete the medication adjustment section of the referral (check acutes as well as repeats)
 - We are unable to progress the referral until it is complete and patients recall the information



NHS Type 2 Diabetes Path to Remission Programme pathway: Primary care focus





- Referrals / contact: momenta.t2dr-llr@nhs.net or 0116 303 2306
- Referrer support sessions https://outlook.office365.com/owa/calendar/T2DRWeeklydropinsessions@momentanewcastle.com/bookings/
- Referrer resources: Eligibility, search, forms, patient info, guidance etc. https://momentanewcastle.com/hcp-t2dr-llr
- Patient landing page: Service overview, eligibility, readiness https://momentanewcastle.com/t2dr-llr
- *SNOMED codes: Momenta will write to practices with all other relevant codes after referral

**The form can be completed by health care professionals other than a GP e.g. practice / diabetes nurses and/or pharmacists as long as the medications adjustments are signed off by a GP or someone they give authority to do so on their behalf.



Agenda



- Welcome, questions, recording
- Background and benefits
- The programme
- Roles and responsibilities, referral pathways
- Medications adjustments
- Searches and referrals

Next steps



Next steps



- Questions / discussion
- Follow-up email and pack
 - Slides, resources, pathway, NHSE guidance, DPIA, recording
- Update colleagues
- Ask us any questions at our weekly Drop-in sessions
- Happy to attend PLT / PCN / other events
- Venues: Let us know (venue requirements on next slide)

• We look forward to your referrals!



T2DR venue requirements



Essential

- Comfortable space for 3 seated participants
- Chairs and a table / desk
- Good local public transport (and parking if needed)
- Clean and appropriately lit and heated / cooled
- Meet accessibility requirements
- Free wifi internet access

Ideally

- Open for extended hours (evenings, weekends)
- Staffed
- Used for other health / community services
- Qualified first aider onsite



Contact details



- Referrals to momenta.t2dr-llr@nhs.net
- Supporting referrals feedback welcome
 - <u>Referrer resources</u>
 - Participant page
- Ongoing support: <u>Register here</u>
- Participant case studies
- Want T2DR delivered at your practice? <u>Register here</u>
- Key contacts:
 - ICB: <u>Becky Hartlett</u>, Diabetes Project Manager or <u>Jeremy</u>
 <u>Bennett</u>, Senior Integration & Transformation Manager LTCs
 - Momenta: Kathryn Brown, Engagement Lead
 - Also <u>Becky Winbow</u>, Contract Manager



Thank you for your time

Becky Winbow Rebecca.winbow@momentanewcastle.com

Kathryn Brown Kathryn.brown@momentanewcastle.com

MFS



MOMENTA NEWCASTLE